CEL-SCI Corp. CVM 深 滬
已收盤 08-29 16:00:00 美东时间
10.43
+1.120
+12.03%
華盛通- 最 高10.87
- 今 開9.12
- 成交量 51.80万股
- 最 低 9.06
- 昨 收 9.31
- 總市值 5355.81万
- 52周最高 39.30
- 市盈率 靜 --
- 換手率 10.09%
- 52周最低 1.98
- 委 比 33.33%
- 總股本 513.50万
- 歷史最高 1425.00
- 量 比 1.01
- 振 幅 19.44%
- 歷史最低 5.40
- 每 手 1
- 風險率 9.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多中金：维持信达生物跑赢行业评级 上调目标价至118.3港元
中金发布研报称，考虑到信达生物（01801）上半年运营盈利能力超预期，上调2025年净利润预测84.3%至8.71亿元，基本维持2026年归母净利润预测1...
08-29 11:59
CEL-SCI股价重挫逾30%，此前宣布完成1000万美元公开发行定价
美股周四早盘，生物技术公司CEL-SCI（CVM）股价重挫30.44%，此前该公司宣布完成1000万美元公开发行定价，以每股9.00美元的价格出售1111...
08-28 22:51
Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Shares of Snowflake Inc. (NYSE:SNOW) rose sharply in pre-market trading after t...
08-28 17:48
Why Is CEL-SCI Stock Crashing After-Hours?
CEL-SCI's shares dropped 38.19% after announcing a $10 million public offering priced below market value to fund its cancer immunotherapy development.
08-28 15:12
CEL-SCI shares drop on proposed public offering
CEL-SCI Corporation (NYSE:CVM) said on Wednesday that it intends to offer to sell shares of its common stock in a best-efforts public offering. All of the shares of common stock are being offered by...
08-28 05:32
CEL-SCI Announces Proposed Public Offering; No Size Or Amount Disclosed
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company,today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants
08-28 05:26
BridgeBio to Present New Acoramidis Data Showing Reduced Cardiovascular Death Risk at ESC 2025
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire oral presentation on additional open-label
08-25 19:46
CEL-SCI Q3 EPS $(1.36) Up From $(4.18) YoY
CEL-SCI (AMEX:CVM) reported quarterly losses of $(1.36) per share. This is a 67.46 percent increase over losses of $(4.18) per share from the same period last year.
08-14 22:47
国金医药甘坛焕丨创新药前瞻深度：从IL-2双抗，看TAA、细胞及趋化因子的PD-1升级新方向
（来源：国金证券研究所） 作者：甘坛焕、赵海春 摘要 背景 创新药BD（授权合作交易）及其首付额爆发，下一个十亿美元首付花落谁家成市场新焦点。（...
08-14 07:34
CEL-SCI Signs MOU With Leading Saudi Pharma; Breakthrough Medicine Designation Filed For Multikine With SFDA, Eyes MENA Expansion
Memorandum of Understanding (MOU) signed with a leading Saudi Arabian pharma company which submitted the Breakthrough Medicine Designation to the Saudi Food and Drug Authority (SFDA)Increasing interest in CEL-SCI from
08-13 21:16
